FMP
Compugen Ltd.
CGEN
NASDAQ
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
1.41 USD
-0.05 (-3.55%)
We are unable to load the chart at this time.
We are unable to load the chart at this time.
Date
Revenue
Earnings
Estimated Earnings
Surprise
2025-03-04
1.47M
-0.07
0.07
-200.00%
2024-11-12
17.13M
0.01
0.06
-83.33%
2024-08-06
6.7M
-0.02
-0.08
-75.00%
2024-05-20
2.56M
-0.08
-0.1
-20.00%
2024-03-05
33.46M
0.11
0.23
-52.17%
2023-11-07
8M
-0.11
-0.09
22.22%
2023-08-07
0
-0.11
-0.13
-15.38%
2023-05-15
0
-0.11
-0.12
-8.33%
2023-02-27
7.5M
-0.04
-0.14
-71.43%
2022-11-14
0
-0.14
-0.13
7.69%
2022-08-04
0
-0.11
-0.12
-8.33%
2022-05-16
0
-0.11
-0.12
-8.33%
2022-02-24
-5.15M
-0.1
-0.15
-33.33%
2021-11-12
6M
-0.07
-0.13
-46.15%
2021-07-28
0
-0.11
-0.12
-8.33%
2021-05-13
0
-0.12
-0.12
0.00%
2021-02-25
2M
-0.1
-0.1
0.00%
2020-11-05
0
-0.09
-0.09
0.00%
2020-07-30
0
-0.08
-0.1
-20.00%
2020-05-06
0
-0.1
-0.1
0.00%
2020-02-20
0
-0.1
-0.11
-9.09%
2019-11-11
0
-0.1
-0.11
-9.09%
2019-08-05
0
-0.1
-0.14
-28.57%
2019-05-20
0
-0.14
-0.17
-17.65%
2019-02-26
0
-0.16
-0.21
-23.81%
2018-11-07
7.8M
-0.05
-0.12
-58.33%
2018-08-01
0
-0.19
-0.19
0.00%
2018-05-09
10M
0
-0.19
-101.05%
2018-02-21
0
-0.18
-0.2
-10.00%
2017-11-07
0
-0.19
-0.19
0.00%
2017-08-02
0
-0.18
-0.17
5.88%
2017-05-09
0
-0.17
-0.18
-5.56%
2017-02-15
53k
-0.17
-0.18
-5.56%
2016-11-07
70k
-0.15
-0.13
15.38%
2016-08-02
496k
-0.13
-0.17
-23.53%
2016-05-10
93k
-0.17
-0.16
6.25%
2016-02-09
8.31M
-0.01
-0.11
-90.91%
2015-11-03
229k
-0.13
-0.15
-13.33%
2015-08-04
223k
-0.14
-0.14
0.00%
2015-05-05
513k
-0.12
-0.13
-7.69%
2015-02-10
6.55M
-0.03
-0.08
-62.50%
2014-10-29
1.72M
-0.11
-0.11
0.00%
2014-08-06
1.96M
-0.07
-0.1
-30.00%
2014-05-19
2.13M
-0.04
-0.11
-63.64%
2014-02-11
1.77M
-0.09
-0.12
-25.00%
2013-10-29
1.59M
-0.12
-0.1
20.00%
2013-08-02
22k
-0.09
0
-
2013-04-25
162k
-0.09
0
-
2013-02-20
134k
-0.15
0
-
2012-11-05
0
-0.1
0
-
2012-09-30
108k
-0.1
0
-
2012-03-31
0
-0.12
0
-
2012-02-07
-424k
-0.13
-0.1
30.00%
2011-11-08
0
-0.1
-0.09
11.11%
2011-08-02
0
-0.06
-0.08
-25.00%
2011-05-11
190k
-0.06
-0.07
-14.29%
2011-02-15
0
-0.06
0
-
2010-09-30
0
-0.05
0
-
2010-07-27
800k
-0.03
-0.06
-50.00%
2010-04-27
125k
-0.08
-0.05
60.00%